Retrospective analysis of severe cutaneous adverse drug reactions over a period of 6 years
DOI:
https://doi.org/10.66344/jpad.v30i4.1442Keywords:
Severe cutaneous adverse reactions, Stevens-Johnson syndrome, toxic epidermal necrolysis, retrospective analysisAbstract
Background severe cutaneous adverse reactions are a group of potentially lethal adverse drug reactions. Prompt diagnosis and management may reduce the morbidity and mortality. Early identification of the offending drug is necessary for early withdrawal and to prevent the recurrences of such a devastating illness.
Aims To study the demography, offending agents, clinical features and treatment, complications, morbidity and mortality of SJS/TEN in our hospital.
Materials and Methods In this retrospective study, we reviewed the medical records of SJS, TEN, SJS/TEN overlap of inpatients over a period of 6 years.
Results Among the 16 patients included, 7 (43,75%) were male with a mean age of 46.2 ± 15 years. Antimicrobials were the commonest group of drugs causing SCAR in 8/16 patients (50%). The most common morbidity noted in our study was due to sepsis leading to acute renal failure. The SCORTEN score for 5 TEN cases ranged from 0 to 5. Two of the SJS/TEN cases died giving a mortality rate of 12.50% (2/16).
Conclusion Antibiotics are the common offending agents of SJS/TEN in our study.
References
Riyaz N, Sasidharanpillai S, Rahima S, Kavitha MM. Toxic epidermal necrolysis following phenytoin and cranial irradiation. Indian J Dermatol.2015;60:424.
Kumar R, Das A, Das S. Management of stevens-johnson syndrome-toxic epidermal necrolysis: Looking beyond guidelines!. Indian J Dermatol. 2018; 63:117-24.
Patel TK, Thakkar SH, Sharma D. Cutaneous adverse drug reactions in Indian population: A systematic review. Indian Dermatol Online J 2014;5:S76-86.
Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau J. Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multiforme. Arch Dermatol. 1993;129(1):92–6.
Peter D, Amirtharaj G J, Mathew T, Pulimood S, Ramachandran A. Role of oxidative and nitrosative stress in pathophysiology of toxic epidermal necrolysis and Stevens Johnson syndrome-A pilot study. Indian J Dermatol. 2015;60:427-31.
Devi K, George S, Criton S, Suja V, Sridevi PK. Carbamazepine – The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years. Indian J Dermatol Venereol Leprol. 2005;71:325-8.
Moutaouakkil Y, Adouani B, Tebaa A, Cherrah Y, Bencheikh RS, Lamsaouri J, & Bousliman Y. Nécrolyse épidermique toxique: une méta-analyse. Médecine thérapeutique.2018; 24(2): 72-88.
Kameshwari JS, Devde R. A case report on toxic epidermal necrolysis with etoricoxib. Indian J Pharmacol 2015;47:221-3.
Paik S, Sen S, Das J, Saha B, Tripathi SK. Allopurinol induced Stevens-Johnson syndrome – A case report. J Clin Diagn Res 2015;9:WJ01-2.
Moutaouakkil Y, El Jaoudi R, El Cadi MA, Derraji S, Serragui S, Bennana A & Bousliman Y. Toxidermies médicamenteuses induites par l’allopurinol et la carbamazépine Analyse de la base de données VigiAccess.Médecine thérapeutique.2018;24(5): 342-7.
Palmieri TL, Greenhalgh DG, Saffle JR, Spence RJ, Peck MD, Jeng JC, et al. A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century. J Burn Care Rehabil.2002;23(2):87‑96.
Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1‑17.
Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and Toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007;56:419-25.
Roujeau JC, Guillaume JC, Fabre JP, Penso D, Fléchet ML, Girre JP. Toxic epidermal necrolysis (Lyell Syndrome): Incidence and drug etiology in France, 1981-1985. Arch Dermatol 1990;126:37-42.
Fiszenson-Albala F, Auzerie V, Mahe E, et al. A 6-month prospective survey of cutaneous drug reactions in a hospital setting. Br J Dermatol 2003; 149: 1018–22.
Gerson D, Sriganeshan V, Alexis JB. Cutaneous drug eruptions: a 5-year experience. J Am Acad Dermatol 2008; 59: 995–9.
Schöpf E, Stühmer A, Rzany B, Victor N, Zentgraf R, Kapp JF. Toxic epidermal necrolysis and Stevens-Johnson syndrome- An Epidemiologic study from West Germany. Arch Dermatol 1991;127:839-42.
Liu W, Nie X, & Zhang L. A retrospective analysis of Stevens–Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids. Int J Dermatol.2016;55(12), 1408-13.
Wang L, Mei XL. Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients. Chin Med J 2017;130:1062-8.
Botelho LF, Porro AM, Enokihara MM, & Tomimori J. Adverse cutaneous drug reactions in a single quaternary referral hospital. Int J Dermatol.2016; 55(4): e198-e203.
Sanmarkan AD, Sori T, Thappa DM, Jaisankar TJ. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis over a period of 10 years. Indian J Dermatol.2011;56:25-9.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Youssef Moutaouakkil, Rachid el Jaoudi, Samira Serragui, Yahia Cherrah, Jamal Lamsaouri, Samir Siah, Yassir Bousliman
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
